1. Circulating cell-free nucleosomes as biomarker for kidney transplant rejection: a pilot study
- Author
-
Verhoeven, J.G.H.P. (Jeroen G. H. P.), Baan, C.C. (Carla), Peeters, A.M.A. (Annemiek M. A.), Clahsen-van Groningen, M.C. (Marian), Nieboer, D. (Daan), Herzog, M. (Mariëlle), Eccleston, M. (Marc), Hesselink, D.A. (Dennis), Boer, K. (Karin), Verhoeven, J.G.H.P. (Jeroen G. H. P.), Baan, C.C. (Carla), Peeters, A.M.A. (Annemiek M. A.), Clahsen-van Groningen, M.C. (Marian), Nieboer, D. (Daan), Herzog, M. (Mariëlle), Eccleston, M. (Marc), Hesselink, D.A. (Dennis), and Boer, K. (Karin)
- Abstract
Background: There is an unmet need for noninvasive markers specific for kidney transplant rejection. Such a marker may eventually overcome the need for a transplant biopsy. In this pilot study, the potential of circulating cell-free nucleosomes (CCFN) to serve as a biomarker for kidney transplant rejection was evaluated. Methods: Forty de novo kidney transplant recipients were prospectively followed as part of a randomized, controlled clinical trial. Total CCFN (H3) and CCFN with the histone modifications H3K36me3 and H3 citrulline were measured in patients at four fixed time points: before transplantation and on days 3–6, 30 and 180 after kidney transplantation. In addition, serum collected at times of transplant rejection (n = 14) was analyzed. CCFN were measured with a Nu.Q™ Assay kit (VolitionRx), an ELISA-based assay using antibodies directed against nucleosomes. Results: For total CCFN (H3), H3K36me3, and H3 citrulline, the same pattern was seen over time: Concentrations were elevated shortly after transplantation (day 3–6) followed by a decline reaching baseline (pre-transplantation) values at days 30 and 1
- Published
- 2021
- Full Text
- View/download PDF